TG Therapeutics Stock Rises on Strong Briumvi Sales and Raised Guidance
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.
/ 907 items
#Healthcare↓
FDA Extends Review Timeline for Travere's FSGS Treatment
FDA delays approval decision for Filspari in rare kidney disease FSGS until April 2026. Travere Therapeutics (TVTX) continues commercial preparations for potential first FSGS treatment.
Moderna Rises as CEO Eyes European Market and Flu-Covid Vaccine
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.
ANKTIVA Shows Promise in Lung Cancer Treatment
ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.
Travere Therapeutics Stock Plunges on FDA Approval Uncertainty
Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.
BofA Raises Biohaven Price Target to $15 on Pipeline Progress, But Stays Cautious
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.